GRI Bio (GRI) Price & Analysis

Compare

196 Followers

GRI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.10 - $30.43

Previous CloseN/A

Volume96.89K

Average Volume (3M)231.77K

Market Cap

$3.50M

Enterprise Value-$2.18M

Total Cash (Recent Filing)$3.28M

Total Debt (Recent Filing)$108.00K

Price to Earnings (P/E)―

Beta2.07

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.31

Shares Outstanding2,515,305

10 Day Avg. Volume107,808

30 Day Avg. Volume231,767

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.62

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit2.18K

Enterprise Value/Ebitda0.19

Forecast

1Y Price Target

$10.00

Price Target Upside619.42% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe Independent Data Monitoring Committee recommended the Phase 2 can continue as planned as no safety concerns were reported.

Market PotentialThe company's initial focus on developing GRI-0621 for Idiopathic Pulmonary Fibrosis presents a large market potential, affecting approximately 140,000 patients in the U.S.

Safety ProfileGRI-0621's maturing favorable safety profile helps de-risk upcoming data readouts while differentiating the molecule in the space.

Bears Say

Clinical Trial RisksDespite high risks associated with clinical trials, the potential market for the company's drugs is substantial, offering high rewards for the risks involved.

Data RequirementsMore patient data is required to appropriately evaluate GRI-0621's full anti-fibrotic effect and capacity to improve pulmonary function.

GRI Bio News

GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF

GRI Bio (GRI) reported interim 6-week biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the...

19d ago

GRI

GRI Bio Stockholders Approve Equity Plan Amendment

GRI Bio ( ($GRI) ) has provided an announcement. On August 13, 2025, GRI Bio, Inc. held its...

6d ago

GRI

Gri Bio, Inc. (GRI) Q2 Earnings Cheat Sheet

Gri Bio, Inc. (GRI) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street...

9d ago

GRI

Buy Recommendation for GRI Bio: Promising Phase 2a Study of GRI-0621 in IPF with Strong Biomarker Strategy

H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on GRI Bio today and set a price target...

15d ago

GRI

GRI Bio Announces Positive Interim Data for GRI-0621

GRI Bio ( ($GRI) ) has provided an update. On July 31, 2025, GRI Bio announced interim biomarker...

19d ago

GRI

Optimistic Buy Rating for GRI Bio Amidst Promising Clinical Trial Developments and Strategic Insights

Matthew Keller, an analyst from H.C. Wainwright, reiterated the Buy rating on GRI Bio (GRI – Research Report)....

2M ago

GRI

GRI Bio completes enrollment in Phase 2a study of GRI-0621

GRI Bio (GRI) announced the completion of patient enrollment for its Phase 2a study evaluating GRI-0621 for the...

2M ago

GRI

GRI Bio Announces Positive Interim Phase 2a Results

GRI Bio ( ($GRI) ) has shared an announcement. On June 26, 2025, GRI Bio announced positive interim...

2M ago

GRI

GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621

GRI Bio (GRI) reported positive 6-week interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for...

2M ago

GRI

Optimistic Buy Rating for GRI Bio Driven by Promising Clinical Developments and Safety Profile

H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on GRI Bio (GRI – Research Report) today and...

2M ago

GRI

GRI Bio Expands Share Offering Agreement

GRI Bio ( ($GRI) ) has provided an update. On May 23, 2025, GRI Bio, Inc. announced an...

3M ago

GRI

GRI Bio presents preclinical data on GRI-0621

GRI Bio (GRI) announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 has anti-inflammatory and...

3M ago

GRI

GRI Bio Advances in IPF Treatment with Promising Trial Results

Gri Bio, Inc. ( ($GRI) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

GRI

GRI Bio expects cash to fund operations through Q3 of 2025

The company reported Q1 results. As of March 31, 2025, the Company had cash and cash equivalents of...

3M ago

GRI

GRI FAQ

What was GRI Bio’s price range in the past 12 months?

GRI Bio lowest stock price was $1.10 and its highest was $30.43 in the past 12 months.

What is GRI Bio’s market cap?

GRI Bio’s market cap is $3.50M.

When is GRI Bio’s upcoming earnings report date?

GRI Bio’s upcoming earnings report date is May 20, 2026 which is in 273 days.

How were GRI Bio’s earnings last quarter?

GRI Bio released its earnings results on Aug 13, 2025. The company reported -$1.312 earnings per share for the quarter, missing the consensus estimate of -$1.31 by -$0.002.

Is GRI Bio overvalued?

According to Wall Street analysts GRI Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GRI Bio pay dividends?

GRI Bio does not currently pay dividends.

What is GRI Bio’s EPS estimate?

GRI Bio’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does GRI Bio have?

GRI Bio has 2,515,305 shares outstanding.

What happened to GRI Bio’s price movement after its last earnings report?

GRI Bio reported an EPS of -$1.312 in its last earnings report, missing expectations of -$1.31. Following the earnings report the stock price went up 3.175%.

Which hedge fund is a major shareholder of GRI Bio?

Currently, no hedge funds are holding shares in GRI

Company Description

GRI Bio

GRI Bio (GRI) is a biotechnology company focused on developing innovative therapies to address unmet medical needs in the field of immunology. The company's core products and services revolve around its proprietary platform technology, which aims to modulate immune system responses to treat chronic inflammatory and fibrotic diseases. GRI Bio operates at the intersection of biotechnology and pharmaceuticals, striving to bring novel therapeutic solutions to market.

GRI Bio (GRI) Earnings & Revenues

Historic Earnings Reports

GRI Stock 12 Month Forecast

Average Price Target

$10.00

▲(619.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","124611":"$124,611","249222":"$249,222","62305.5":"$62,305.5","186916.5":"$186,916.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,62305.5,124611,186916.5,249222],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.9876923076923076,2.6553846153846155,3.323076923076923,3.9907692307692306,4.658461538461538,5.326153846153846,5.993846153846154,6.661538461538462,7.32923076923077,7.9969230769230775,8.664615384615384,9.332307692307692,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.9876923076923076,2.6553846153846155,3.323076923076923,3.9907692307692306,4.658461538461538,5.326153846153846,5.993846153846154,6.661538461538462,7.32923076923077,7.9969230769230775,8.664615384615384,9.332307692307692,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.9876923076923076,2.6553846153846155,3.323076923076923,3.9907692307692306,4.658461538461538,5.326153846153846,5.993846153846154,6.661538461538462,7.32923076923077,7.9969230769230775,8.664615384615384,9.332307692307692,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":228801.66,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":249221.8,"date":1638316800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":549.18,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.69,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.7,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.1,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.08,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >